RE:RE:Excellent result from Johnson & Johnson Time to put one thing in logical, rational business sense: Symrise's relationship with Ceapro. More specifically, from a revenue perspective.
- FACT: Materially all (94%) of Ceapro's revenue comes from Symrise
- 2022 FS, Section 15
- FACT: Ceapro's revenue from Symrise amounts to $17,638,541 CAD
- 2022 FS, Section 15
- ASSUMPTION: Symrise marks-up what it buys from Ceapro by 100%, Symrise's revenue coming from Ceapro amounts to $35,277,082 CAD
- FACT: Symrise's aggregate revenue for 2022 was $6,696,825,000 CAD
- Converted at 1.45 CAD to Euro
Sooo... and I think you get the idea by now, Ceapro's contribution to Symrise's revenue is immaterial, IMMATERIAL. It represents 0.53% of Symrise's aggregate revenue, at best.
Who does everyone think has the power here?!!!
FACT: If Symrise walks away from Ceapro, Symrise loses a wart on its bottom... meanwhile, Ceapro disappears from the earth.
This is the writing on the wall and Q2-2023 revenues will determine if it is written in permanent ink.
Gilles Gagnon, and Gilles Gagnon alone, is responsible for the state of Ceapro and the fact - yes, I think it is a fact - that will soon disappear from the earth.
FACT: This is evidenced by the immaterial spend Gilles Gagnon has made in recent years on Sales & Marketing...
AND...
FACT: GILLES GAGNON HAS NOT DEVELOPED NOR BROUGHT TO MARKET ONE SINGLE NEW PRODUCT IN HIS ENTIRE 11+ YEAR TENURE AS CEO.
FACT: Gilles Gagnon has published a toooooonnne of meaningless press releases over the years... their meaninglessness is evidenced by way in which the market has rewrded the share price.
Dem be the facts folks.
PS Thank you for removing my previous version of this post, I know the word I used for 'bottom' wasn't the reason.
Your removal of my post made this version even better!